Learn more at LeadIQ.com

Insights

Innovative Therapy Platform Carmine Therapeutics specializes in non-viral gene therapies utilizing red blood cell extracellular vesicles, presenting a unique approach that appeals to biotech companies seeking alternative delivery mechanisms and novel treatment modalities.

Strategic Partnerships The company's recent alliance with Takeda Pharmaceuticals and recognition as a Fierce 15 biotech indicate strong industry validation and potential for collaboration, making it an attractive partner or client for biotech procurement and licensing opportunities.

Funding & Growth Potential With initial investments of $3.5 million and milestones-driven funding, Carmine is in a growth phase, creating opportunities to offer tailored technology services, research collaborations, or strategic investments to accelerate development pipelines.

Emerging Market Presence Being recognized as a promising biotech company and expanding U.S. operations position Carmine as a key player in the gene therapy landscape, presenting opportunities for sales of lab equipment, research tools, and contract research services.

Focus on Rare Diseases Development of therapies for rare diseases offers a niche market with high unmet needs, opening avenues for specialized biotech services, regulatory consulting, or funding support tailored to innovative gene therapy projects.

Similar companies to Carmine Therapeutics

Carmine Therapeutics Tech Stack

Carmine Therapeutics uses 8 technology products and services including Google Analytics Enhanced eCommerce, Wix, Google Cloud, and more. Explore Carmine Therapeutics's tech stack below.

Google Analytics Enhanced eCommerce
Analytics
Wix
Content Management System
Google Cloud
Infrastructure As A Service
RequireJS
Javascript Frameworks
Lodash
Javascript Libraries
Zepto
Javascript Libraries
Bootstrap
UI Frameworks
Google Analytics
Web Analytics

Media & News

Carmine Therapeutics's Email Address Formats

Carmine Therapeutics uses at least 1 format(s):

Carmine Therapeutics Email Formats	Example	Percentage
First.Last@carminetherapeutics.com	John.Doe@carminetherapeutics.com	48%
FLast@carminetherapeutics.com	JDoe@carminetherapeutics.com	2%
First.Last@carminetherapeutics.com	John.Doe@carminetherapeutics.com	48%
FLast@carminetherapeutics.com	JDoe@carminetherapeutics.com	2%

Frequently Asked Questions

Where is Carmine Therapeutics's headquarters located?

Carmine Therapeutics's main headquarters is located at 700 Main Street Labcentral Cambridge, Massachusetts United States. The company has employees across 3 continents, including North AmericaAsiaSouth America.

What is Carmine Therapeutics's official website and social media links?

Carmine Therapeutics's official website is carminetherapeutics.com and has social profiles on LinkedIn Crunchbase.

What is Carmine Therapeutics's SIC code NAICS code?

Carmine Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Carmine Therapeutics have currently?

As of March 2026, Carmine Therapeutics has approximately 6 employees across 3 continents, including North AmericaAsiaSouth America. Key team members include Chief Executive Officer And Director: D. H.Vice President, Discovery: Q. Y.Associate Director: M. W. U. H.. Explore Carmine Therapeutics's employee directory with LeadIQ.

What industry does Carmine Therapeutics belong to?

Carmine Therapeutics operates in the Biotechnology Research industry.

What technology does Carmine Therapeutics use?

Carmine Therapeutics's tech stack includes Google Analytics Enhanced eCommerceWixGoogle CloudRequireJSLodashZeptoBootstrapGoogle Analytics.

What is Carmine Therapeutics's email format?

Carmine Therapeutics's email format typically follows the pattern of First.Last@carminetherapeutics.com. Find more Carmine Therapeutics email formats with LeadIQ.

When was Carmine Therapeutics founded?

Carmine Therapeutics was founded in 2019.

Carmine Therapeutics

Biotechnology ResearchMassachusetts, United States2-10 Employees

Carmine Therapeutics, headquartered in Cambridge MA, is pioneering a new class of non-viral gene therapies based on red blood cell extracellular vesicles, combined with proprietary payloads. In June 2020, Carmine inked a research alliance with Takeda Pharmaceuticals worth up to $900 million to develop non-viral gene therapies for 2 targets. Carmine has also been named one of the FierceBiotech’s Fierce 15 Biotech companies of 2020 and was also awarded the Bristol-Myers Squibb "Golden Ticket". Carmine was founded in 2019 by EVX Ventures, Professors Harvey Lodish (Whitehead, MIT), Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme and Millennium Pharmaceuticals, is also Chair of the Scientific Advisory Board of Carmine.
 
For more information, visit www.carminetherapeutics.com
 
Media Relations
Media@carminetherapeutics.com
 
Investor Relations
Investors@carminetherapeutics.com

Company Overview

Headquarters: 700 Main Street Labcentral Cambridge, Massachusetts United States
Website: carminetherapeutics.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2019
Employees: 2-10

Media & News

Funding & Financials

$1M
Carmine Therapeutics's revenue is estimated to be in the range of $1M

Funding & Financials

$1M
Carmine Therapeutics's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.